Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Price Performance Shares of NASDAQ GLMD opened at $0.31 on Friday. Galmed Pharmaceuticals has a 12-month low of $0.26 and a 12-month high […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Galmed Pharmaceuticals Ltd ,Galmed Pharmaceuticals Price Performance ,Hedge Funds Weigh In On Galmed Pharmaceuticals ,Raymond James Financial Services Advisors Inc ,Galmed Pharmaceuticals Company Profile ,Walleye Capital ,Cambridge Investment Research Advisors Inc ,Galmed Pharmaceuticals ,Millennium Management ,News Ratings For Galmed Pharmaceuticals Daily ,Free Report ,Investment Research Advisors ,James Financial Services Advisors ,Get Free Report ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,